News: Urologic Cancers

The Kidney Cancer Association is recognizing the research accomplishments and leadership achievements of W. Kimryn Rathmell, MD, PhD, with its top honor, the Eugene P. Schonfeld Award.

Brian Rini, MD, an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development, is joining Vanderbilt-Ingram Cancer Center as the inaugural chief of Clinical Trials.

Some of the nation’s leading genitourinary cancer physicians will speak about the latest advances in care at an OncLive State of the Science Summit held in collaboration with Vanderbilt-Ingram Cancer Center.

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk.

Vanderbilt collaborators focused on minimally invasive prostate surgery are developing an endoscopic robotic system with two-handed dexterity at a much smaller scale than existing options.

The Vanderbilt Institute for Surgery and Engineering (VISE) team of Robert Webster III, PhD, and Duke Herrell, MD, have received a $2.2 million grant from the National Institutes of Health to develop a new surgical robot for endoscopic transurethral prostatectomy.

Joseph “Jay” Smith Jr., MD, professor of Urologic Surgery, has been awarded the 2019 Willet F. Whitmore Jr. Award and Lectureship from the Society of Urologic Oncology (SUO).

A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.

Daniel Barocas, MD, MPH, associate professor of Urology, is being recognized with a national award from the Society of Urologic Oncology (SUO) for his efforts to develop urologic cancer quality measures.

Vanderbilt urologic surgeons are offering an alternative therapy for prostate cancer patients considered to be low-to-intermediate risk, a middle ground between active surveillance and aggressive therapy.